Aims: To examine whether the prophylactic antianginal agent perhexiline potentiates platelet responsiveness to nitric oxide (NO) in patients with stable angina pectoris (SAP) and acute coronary syndromes (ACS: unstable angina pectoris or non-Q-wave myocardial infarction). Methods and Results: Blood samples were obtained from patients before and after initiation of treatment with perhexiline. ADP-induced platelet aggregation and its inhibition by the NO donor sodium nitroprusside (SNP) were determined via impedance aggregometry in whole blood (WB) and platelet-rich plasma (PRP). Intraplatelet cGMP content was assayed by RIA, and superoxide (O2-) level by lucigenin-derived chemiluminescence. In patients with ACS not receiving perhexiline (n = 12), platelet responsiveness to SNP did not vary significantly over the first 3 days post admission to hospital. Therapy with perhexiline for 3 days was associated with increases in SNP-induced inhibition of aggregation from 29 ± 2% to 43 ± 4% (n = 50, P<0.001) in WB and from 20 ± 5% to 42 ± 7% (n= 12, P<0.01) in PRP. Resolution of symptomatic ischaemia (n = 39) was associated with significantly greater (P<0.01) increases than non-resolution (n = 11). Similar increases in SNP responsiveness (P<0.001) occurred following institution of perhexiline therapy in patients with SAP (n = 30), associated with a 85% decrease in anginal frequency. Treatment with perhexiline potentiated the cGMP-elevating effects of SNP in platelets (n = 9, P = 0.03). Although perhexiline did not alter whole blood O2- concentration ex vivo, it inhibited (P<0.01) O2- release from neutrophils in vitro. Conclusion: Perhexiline potentiates platelet responsiveness to NO both in SAP and ACS patients; in the latter group this improvement was predictive of resolution of ischaemic symptoms. The predominant mechanism of perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for NO clearance by neutrophil-derived O2-.
- Nitric oxide